Condition: Breast Cancer · Endometrial Cancer · Ovarian Cancer · Sponsor: Terremoto Biosciences Inc.
This is a Phase 1/2, open-label, multicenter study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics and anti-tumor activity of TER-2013 in patients with advanced solid tumors harboring AKT/PI3K/PTEN pathway alterations.
This description comes directly from the study's public registry record.
Terremoto Biosciences, Inc. Clinical Trials Central Contact · 888-682-1551 · clinicaltrials@terremotobio.com
Always discuss trial participation with your own doctor first.
| Florida Cancer Specialists - Lake Nona | Orlando, Florida, United States | Recruiting |
| Massachusetts General Hospital | Boston, Massachusetts, United States | Recruiting |
| Mayo Rochester | Rochester, Minnesota, United States | Recruiting |
| Washington Univ. School of Medicine | St Louis, Missouri, United States | Recruiting |
| Nebraska Cancer Specialists | Omaha, Nebraska, United States | Recruiting |
| Carolina BioOncology Institute | Huntersville, North Carolina, United States | Recruiting |
| UH Cleveland Medical Center | Cleveland, Ohio, United States | Recruiting |
| Sarah Cannon Nashville | Nashville, Tennessee, United States | Recruiting |
| NEXT Oncology | Austin, Texas, United States | Recruiting |
| MD Anderson Cancer Center | Houston, Texas, United States | Recruiting |
| START Center for Cancer Research | San Antonio, Texas, United States | Recruiting |
| START Center for Cancer Research | West Valley City, Utah, United States | Recruiting |
+ 3 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07109726